HBV reactivation in patients with rheumatoid arthritis treated with anti-interleukin-6: a systematic review and meta-analysis.
Stamatia KatelaniGeorge E FragoulisAthanasios-Dimitrios BakasisAbraham PouliakisElena NikiphorouFabiola AtzeniTheodoros AndroutsakosPublished in: Rheumatology (Oxford, England) (2023)
Overall, anti-IL-6 treatment comes with a significant risk of HBVr in RA patients with CHB; risk is diminished when antiviral prophylaxis is used. In contrast, in RA patients with resolved HBV infection, the risk of HBVr seems to be extremely low. Large, well-designed studies (either controlled trials or multicentre/international observational studies) are warranted to further validate these results.
Keyphrases
- hepatitis b virus
- rheumatoid arthritis
- liver failure
- disease activity
- magnetic resonance
- clinical trial
- study protocol
- randomized controlled trial
- magnetic resonance imaging
- systemic lupus erythematosus
- interstitial lung disease
- combination therapy
- computed tomography
- case control
- contrast enhanced
- double blind
- replacement therapy
- smoking cessation